Kornimate/medical-research-clean huggingface dataset:
risk of post transfusion hepatitis c virus infection

Conditions: Hepatitis, Viral, Human; Blood Transfusion; Blood Donors

Summary: to determine the risk of transfusion-transmitted hepatitis c virus (hcv) in cardiac surgery patients before and after donor screening for anti-hcv and surrogate markers of non-a, non-b hepatitis (nanbh). also, to characterize donors who were hcv seronegative and who lacked surrogate markers at the time of donation, but whose recipient seroconverted to hcv.

background: in the early 1990s, posttransfusion nanbh, mainly caused by hcv, was the most common serious complication of transfusions, occurring in 2-5 percent of transfusion recipients. about 50 percent of those infected developed chronic hepatitis, of whom, 10 to 20 percent developed cirrhosis. hepatocellular carcinoma had been reported to occur in some. this study provided the first evaluation of the effectiveness of donor screening for anti-hcv by the then recently licensed hcv antibody test and surrogate markers of nanbh. it also provided a precise estimate of the risk of transfusion-transmitted hcv. the results allowed examination of risk factors for hcv infected donors who were seronegative at the time of donation. design narrative: the study was a nonconcurrent prospective, seroepidemiologic study. to estimate the incidence of hcv infection, six-month postoperative serum samples were tested for antibody to hcv. preoperative samples corresponding to positive postoperative sera were also tested. the donors of a patient who received blood screened for hcv, i.e., a donation since may, 1990, and seroconverted in the six months since transfusion were located and retested for antibodies to hcv. the donors were administered a questionnaire designed to ascertain risk factors for hcv infection. a sample of donors who were hcv positive at the time of donation were given the same questionnaire. comparison of these three groups of donors (i.e., seropositives, donors tested negative but implicated in seroconversion, seronegatives) allowed an investigation of factors associated with false negative screening results. analytical methods included standard methods for contingency tables and both conditional and unconditional logistic regression. the study completion date listed in this record was obtained from the "end date" entered in the protocol registration and results system (prs) record.

Eligibility criteria:
no eligibility criteria
reducing operative and post-operative morbidity in living kidney donors with the airseal system

Conditions: Pain

Summary: the purpose of this study is to determine if the airseal system will reduce post-operative pain and reduce the need for narcotics in laparoscopic living kidney donor surgeries.

our hypothesis is that airseal insufflation system will provide reduced mean operative insufflation pressure and operative mean etco2, resulting in improved post-operative pain control and improved operative safety. the airseal system has demonstrated decreased variability in intra-abdominal pressure, less post-operative shoulder pain, lower mean etco2 and reduced narcotic pain administration. these metrics have been demonstrated in human subjects undergoing gynecologic, urologic and bariatric procedures. the established benefits in a human model provide a foundation for translating this technology to living kidney donors. the advantage lies in the ability to improve pain-related outcomes in this population, which translates into increased living donation; the single solution to reduce mortality for patients suffering from end-stage kidney disease.

Eligibility criteria:
inclusion criteria: * any living donor who has been approved to donate a kidney is eligible to participate. exclusion criteria: * none

Keywords: living kidney donors
xylitol bsi multisite - reduction of bloodstream infections from oral organisms in pediatric stem cell transplant

Conditions: Allogeneic Stem Cell Transplantation

Summary: bloodstream infections (bsi) caused by bacteria translocating across injured oral mucosa are a significant cause of morbidity and mortality in patients undergoing stem cell transplantation (sct). unfortunately, there are currently no known strategies to prevent these bsi in this vulnerable population. the investigators will conduct a randomized, double-blind, placebo-controlled trial at three institutions to evaluate the effectiveness of twice daily intraoral xylitol-wipe application on reducing bsi in pediatric sct patients.

patients will be randomized to receive either twice-daily intraoral grape-flavored xylitol-wipe (intervention arm) or grape-flavored saline wipe (control arm) application in addition to the current standard of care (soc). the purpose of this study is to determine whether xylitol wipes are effective at reducing bloodstream infections (bsis), dental plaque, mucositis (redness and ulcers in the mouth), or gingivitis in patients who undergo allogeneic stem cell transplant (sct).

Eligibility criteria:
inclusion criteria: * provide signed and dated informed consent and assent (when applicable) form * willing to comply with all study procedures and be available for the duration of the study * admitted and planning to undergo an allogeneic stem cell transplant (sct) at cincinnati children's hospital medical center (cchmc), boston children's hospital, or children's hospital of colorado (denver). * male or female, 4 months to 25 years of age at the time of sct (day 0) * have a minimum of one tooth * agree to avoid chewing gum and toothpaste that contains xylitol during the intervention period exclusion criteria: * prior radiation treatment for cancer of the oral cavity, head, or neck in the past 6 months per the study participant's medical record * cranial boost in patients receiving total body irradiation * known history of allergy to xylitol * known history of allergy to grapes or grape flavoring * undergoing a conditioning-free allogeneic stem cell transplant (patient does not receive any chemotherapy or radiation prior to stem cell infusion)

Keywords: bloodstream infections oral health xylitol dental health gingivitis mucositis plaque
liver transplantation for hepatocellular carcinoma arising in non-cirrhotic liver: a propensity score-matched retrospective cohort study of two national databases

Conditions: Hepatocellular Carcinoma, Non-cirrhotic Liver

Summary: background: majority of liver transplantation (lt) recipients for hepatocellular carcinoma (hcc) were concomitant with liver cirrhosis, while few researches focusing on recipients without cirrhosis. here we aim to investigate the prognosis of non-cirrhosis hcc recipients, expecting to provide theoretical basis for further improvement of these patients. methods: this retrospective study analyze outcomes between adult hcc recipients arising in non-cirrhotic and cirrhotic liver from two national databases (cltr and unos, january 2015 to december 2020). based on important variables, 1:2 and 1:1 propensity score matching (psm) were performed respectively.


Eligibility criteria:
inclusion criteria: * liver transplants, performed from january 2015 to december 2020 exclusion criteria: * pediatric lt; lt for non-tumor lesions; lt for other malignant tumors (cholangiocarcinoma, carcinoma of gallbladder, mixed carcinoma, and secondary tumors); re-transplantation or combined liver-kidney transplantation; incomplete laboratory or clinical data; death within 1 week due to post-operative hemorrhage after lt.
assessment of the prevalence of extended-spectrum betalactamase producing enterobacteriaceae among icu staff

Conditions: Antibiotic Resistance; Extended-spectrum Betalactamase; Enterobacteriaceae; Escherichia Coli

Summary: evaluation of the prevalence of esbl-enterobacteriaceae colonization among icu staff

prospective epidemiological study with voluntary non-medical staff member (i.e. nurses and nursing assistants) and medical staff in two french icus. assessment of self-reported risk factors for mdr-bacteria colonization. self-performed rectal swab with isolation of esbl-producting enterobacteriaceae, identification of bacterial species and antibiotic suspectibilities. characterization of escherichia coli esbl.

Eligibility criteria:
inclusion criteria: * volunteers exclusion criteria: -

Keywords: critical care nursing staff medical staff extended-spectrum betalactamase digestive tract colonization cross-contamination
inflammation and electroconvulsive therapy

Conditions: Major Depressive Disorder

Summary: the purpose of this study is to explore whether electroconvulsive therapy (ect) accidentally leads to a side effect of brain inflammation. patients with treatment resistant depression who are planning to take ect will be subsequently approached to participate in the study.

the first scan will take place before the first ect session. the second scan will occur after a minimum of six ect sessions (average 2.5 weeks). secondary measures will include mood symptom severity, neurocognitive measures, peripheral inflammatory markers and tspo genotype. the hypothesis is that neuroinflammation will be increased by ect. there will be no alterations to standard care of depressed patients due to participation in the study.

Eligibility criteria:
inclusion criteria: * stable physical health * diagnosis of non-psychotic, non-catatonic, major depressive disorder, either unipolar or bipolar and a non-response to at least three clinical trials at appropriate dose of antidepressant medication from at least three different pharmacological classes * at least a 17 on the17-item hdrs despite taking antidepressant treatment prior to ect * have not received ect within the last 12 weeks exclusion criteria: * currently pregnant * current substance abuse or dependence * neurological or unstable medical illness * use of anti-inflammatory drugs within the past month * diazepam or other benzodiazepine use within the past month, except for lorazepam and clonazepam
a study comparing continuous sciatic nerve block to single shot sciatic nerve block

Conditions: Fracture of Foot

Summary: the purpose of this study is to compare the incidence of postoperative symptoms of neurologic injury after a single shot infragluteal-parabiceps sciatic nerve block versus a continuous infragluteal-parabiceps sciatic nerve catheter.

there are a limited number of prospective studies in the literature examining the risk of neurologic injury and symptoms after sciatic nerve blocks. the incidence of transient neurological symptoms after a continuous catheter is not well reported.

Eligibility criteria:
inclusion criteria: * all patients ( ≥18 and ≤ 80) who are scheduled to undergo elective scheduled foot surgery and agreed to receive a sciatic nerve catheter as a part of their postoperative pain management. this study. exclusion criteria: * history of hemostatic abnormalities * chronic pain syndrome * a foot deformity restricting normal foot movement * severe liver or renal disease * a preexisting neurologic disorder * patient refusal to participate * the presence of language barrier that prohibits proper communication with patient.

Keywords: sciatic nerve block continuous nerve block
a trial to compare the safety of once weekly dosing of somapacitan with daily norditropin® flexpro® for 26 weeks in previously human growth hormone treated adults with growth hormone deficiency

Conditions: Adult Growth Hormone Deficiency; Growth Hormone Disorder

Summary: this trial is conducted in europe and asia. the aim of the trial is to compare the safety of once weekly dosing of somapacitan (administered with an investigational pen) with daily norditropin® flexpro® (somatropin delivered within a prefilled pen) for 26 weeks in previously human growth hormone (hgh) treated adults with growth hormone deficiency.


Eligibility criteria:
inclusion criteria: - male or female of at least 18 years of age and not more than 79 years of age at the time of signing informed consent - adult growth hormone deficiency diagnosed for 6 months or longer (defined as 180 days) prior to screening - treatment with hgh (human growth hormone) for at least 6 months at screening - if applicable, hormone replacement therapies for any other hormone deficiencies, adequate and stable for at least 90 days prior to randomisation as judged by the investigator exclusion criteria: - active malignant disease or history of malignancy. exceptions to this exclusion criterion: resected in situ carcinoma of the cervix and squamous cell or basal cell carcinoma of the skin with complete local excision. / subjects with ghd (growth hormone deficiency) attributed to treatment of intracranial malignant tumours or leukaemia, provided that a recurrence-free survival period of at least 5 years is documented in the subject's file - for patients with surgical removal or debulking of pituitary adenoma or other benign intracranial tumour within the last 5 years: evidence of growth of pituitary adenoma or other benign intracranial tumour within the last 12 months (defined as below or equal to 365 days) before randomisation. absence of growth must be documented by two post-surgery mri or ct scans. the most recent mri or ct scan must be performed below or equal to 9 months (defined as below or equal to 270 days) prior to randomisation
safety of nasal influenza immunisation in egg allergic children

Conditions: Egg Hypersensitivity

Summary: egg allergy is common in early childhood, affecting at least one in 50 preschool children. influenza ("'flu") vaccines contain egg protein, as the vaccine is cultured in hen's eggs. there is robust data to support the safety of influenza vaccines (containing low or negligible amounts of egg protein) in patients with egg allergy. a new influenza vaccine, known as laiv (live attenuated intranasal vaccine) has recently been approved by a number of licensing boards and is given by a spray into the nose. this new vaccine has been available in the united states for several years and is highly effective and against influenza infection, with an excellent safety profile in children without egg allergy. however, laiv is also grown in hen's eggs and contains egg protein, and there are no existing data on the safety of laiv in egg-allergic children. the objective of this multicentre study is to assess the safety of intranasal laiv in egg-allergic children, in order to demonstrate that these children can safely be given the new laiv within a primary care health environment.


Eligibility criteria:
inclusion criteria: * aged 2 - 17 years old * physician-diagnosis of egg allergy exclusion criteria: * contraindicated as acutely unwell or current unstable asthma * use of asthma reliever medication in last 72 hours * recent administration of a medication containing antihistamine within the last 4 days * current oral steroid for asthma exacerbation or course completed within last 2 weeks * contraindications to ingredient in laiv (notwithstanding allergy to egg protein) * previous allergic reaction to an influenza vaccine * children and adolescents who are clinically immunodeficient due to conditions or immunosuppressive therapy such as: acute and chronic leukaemias; lymphoma; symptomatic hiv infection; cellular immune deficiencies; and high-dose corticosteroids. * children and adolescents younger than 18 years of age receiving salicylate therapy because of the association of reye's syndrome with salicylates and wild-type influenza infection.

Keywords: egg allergy anaphylaxis children influenza vaccine
salivary oxytocin as a biomarker in psychedelic assisted psychotherapy

Conditions: Depression, Anxiety

Summary: the main objective of this pilot study is to obtain preliminary data on the reactivity of salivary oxytocin during a single lsd intake as part of pap treatment for anxiety disorders or depression (treatment authorisations granted in advance by the federal officie of public health for compassionate use of the substance). there will be no interference with the usual clinical routine in our service. the protocol is only for taking additional saliva measurements to measure oxytocin levels on the day of treatment. participants will be asked to give 4 saliva samples the day of their lsd treatment .in addition they will fill-in self-report questionnaires which are part of the clinical routine


Eligibility criteria:
inclusion criteria: * ongoing psychotherapy with a certified psychotherapist, anxiety disorder or depression resistant to usual treatments, agreement to stop necessary medication exclusion criteria: * exclusion: psychotic or bipolar disorder, high suicidal risk, severe cardiovascular disease, severe liver disease, neurological disease of the central nervous system, pregnancy and breastfeeding
dexamethasone efficacy in hellp i syndrome

Conditions: HELLP Syndrome

Summary: the purpose of this study is to determine the efficacy of dexamethasone for treatment of hellp i (hemolysis, elevated liver enzymes and low platelet count) syndrome.

treatment of hellp syndrome usually is restricted to measures of support and treatment of complications. in 2005, in a subgroup analysis we showed that, among patients with hellp 1, there were a shorter average time to platelet recovery and less duration of hospitalization in women who received dexamethasone therapy, however the importance of this finding is diminished because this was an unplanned analysis and the severity of the disease was not taken into account at randomization.

Eligibility criteria:
inclusion criteria: * women who were at \>20 weeks of gestation or during the first 3 days of puerperium if hypertension developed during the pregnancy or the puerperium with: * platelet count, \ or = 70 u/l; lactate dehydrogenase (ldh), \> or = 600 u/l. * women who consent to be included informed consent by signature exclusion criteria: * diabetic ketoacidosis * oral temperature \> 37.5 grade * contraindication for use steroids

Keywords: hellp 1 dexamethasone clinical trial
revcore for in stent thrombosis

Conditions: In-stent Thrombosis

Summary: the purpose of this research is to collect information about how the revcore thrombectomy catheter works to treat stent blockages.


Eligibility criteria:
inclusion criteria: 1. age ≥ 18 years 2. patients with stent age \> 6 weeks 3. location of thrombosed stents in proximal lower extremity deep vein segments including at least common femoral, external iliac, or common iliac vein 4. revcore thrombectomy catheter must enter vasculature 5. willing and able to provide informed consent exclusion criteria: 1. exposed stents with broken struts, significantly deformed struts, struts protruding into the vessel 2. stents not wall apposed 3. stents compressed to \<10mm 4. bilateral in-stent thrombosis 5. congenital anatomic anomalies of the iliac veins 6. allergy, hypersensitivity, or thrombocytopenia from heparin or iodinated contrast agents, except for mild to moderate contrast allergies for which pretreatment can be used 7. any contraindication to anticoagulants or antiplatelets that, in the opinion of the investigator, cannot be medically managed throughout the study period 8. chronic non-ambulatory status 9. known hypercoagulable states (e.g. antiphospholipid syndrome) that, in the opinion of the investigator, cannot be medically managed throughout the study period 10. inability to secure venous access 11. subject has any condition for which, in the opinion of the investigator, participation would not be in the best interest of the subject 12. current participation in another investigational drug or device treatment study
passive prophylaxis of lyme disease using permethrin treated clothes

Conditions: Lyme Disease

Summary: hypothesis: does treatment of lower extremity clothing with permethrin prevent lyme disease? this is a double-blind, randomized clinical trial using permethrin treatment of clothing to prevent lyme disease.

this is a double-blind, randomized clinical trial using permethrin treatment of clothing to prevent lyme disease. subjects (n=200) will be recruited from camp staff to participate in the study and screened by inclusion and exclusion criteria.qualifying subjects will be randomized to either the treatment (n=100) or non-treatment arm (n=100). subjects in the treatment arm will have their scout shorts, pants, and socks sprayed with 0.5% permethrin and allowed to dry. subjects in the non-treatment arm will have their scout shorts, pants, and socks sprayed with water and allowed to dry. subjects will then be followed over the summer camping season to see if they develop lyme disease. at 70 days, all subjects will have their lyme titers rechecked to ensure that all cases of lyme disease were documented. following the 70 day visit, there will be an assessment of the final study outcomes.

Eligibility criteria:
inclusion criteria: * summer camp staff at tomahawk scout reservation * works in an outdoor environment * sleeps in an outdoor environment (platform tent) * present for the entire camp season (june - august) * informed consent exclusion criteria: * contraindication, allergy or previous reaction to permethrin * inability of subject or surrogate (e.g., parent if \< 18 years of age) to provide informed consent

Keywords: lyme disease tick
sintilimab combined with chemotherapy and radiotherapy in newly diagnosed metastatic nasopharyngeal carcinoma: a multicenter study

Conditions: Nasopharyngeal Carcinoma

Summary: to explore the progression-free survival rate (progression-free survival, pfs), overall survival (os), objective response rate(objective response rate, orr) and safety of patients with sintilimab + gp chemotherapy combined with radiotherapy for newly diagnosed metastatic npc.


Eligibility criteria:
inclusion criteria: * pathologically diagnosed nasopharyngeal cancer with distant metastasis; not received anticancer treatment. * ecog score (ps score) 0 or 1. * neutrophil count \> 1.5\*10\^9/l, hemoglobin \> 90g/l, and platelet count \> 100\*10\^9/l. * alt or ast level \< 2.5 times upper normal limit (upper limit of normal, uln), bilirubin level \< 1.5 times uln. * creatinine clearance level \> 60 ml/min. * patients must sign an informed consent and must be willing and able to comply with the visit, treatment protocol, laboratory tests and other requirements specified in the study protocol. * pregnant female subjects must agree to use reliable contraception within 1 year from the screening visit to the last sintilimab administration. exclusion criteria: * age\> 65 years old or \<18 years old. * hbsag positive and hbv dna\> 10\*10\^3 copy number/ml. * hcv antibody positive. * active, known, or suspected autoimmune diseases. subjects with type i diabetes, hypothyroidism with only hormone replacement therapy, and skin disease without systemic treatment (such as vitiligo, psoriasis, or alopecia) can be selected. * a history of interstitial lung disease. * received systemic hormone or other immunosuppressive therapy with an equivalent dose of\> 10mg of prednisone per day within 28 days prior to signing the informed consent. subjects with a systemic hormone dose of 10mg prednisone per day or inhaled / topical corticosteroids may be enrolled. * received or will be vaccinated within 30 days before signing the informed consent. * pregnancy or breastfeeding women (pregnancy tests should be considered). * other malignancies within 5 years, except carcinoma in situ, fully treated non-melanoma skin cancer, and papillary thyroid carcinoma. * previous allergies to macromolecular protein preparations, or any component of sintilimab. * human immunodeficiency virus (hiv) infection. * other conditions that may affect the safety or trial compliance of the subject, including symptomatic heart failure, unstable angina, myocardial infarction, active infection requiring systemic treatment, mental illness or family and social factors.